Evidence for the proximity of the extreme N-terminus of the neurokinin-2 (NK2) tachykinin receptor to Cys167 in the putative fourth transmembrane helix

被引:7
作者
Bhogal, N [1 ]
Blaney, FE
Ingley, PM
Rees, J
Findlay, JBC
机构
[1] Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England
[2] GlaxoSmithKline NFSP N, Computat Analyt & Struct Sci, Harlow CM19 5AW, Essex, England
关键词
D O I
10.1021/bi035475s
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurokinin-2 receptor (NK2R) binding of [H-3]-SR48968, a piperidinyl antagonist, is inhibited by methanethiosulfonate ethylammonium (MTSEA) in a time- and concentration-dependent manner. By the systematic alanine replacement of putative loop and transmembrane region cysteine residues (CyS4, Cys(81) Cys(167), Cys(262), Cys(281), Cys(301), and Cys(309)), we have determined that MTSEA perturbs [H-3]-SR48968 binding by modifying Cys(167) in transmembrane helix 4. Data were substantiated using glycine, serine, and threonine substitutions of Cys(167). MTSEA preferentially modifies cysteine residues that are in proximity to a negatively charged environment. Hence, aspartate and glutamate residues were systematically substituted with leucine or valine, respectively, and the inhibitory effects of MTSEA on [H-3]-SR48968 binding were reevaluated to determine those acidic residues close to the MTSEA binding crevice. Most significantly, substitution of Asp(5) in the receptor's extreme N-terminus abolished the effects of MTSEA on [H-3]SR48968 binding. Therefore, our data would suggest close association of the extreme N-terminus with the extracellular surfaces of helices 4 and 3 in the NK2R in forming a binding crevice for MTSEA. The inhibition of SR48968 binding appears to result from loss of the SR48968 binding conformation of Gln(166) induced by MTSEA when it is coupled to Cys167. Hence, it is proposed that there is mutually exclusive hydrogen bonding of SR48968 and MTSEA to Gln(166).
引用
收藏
页码:3027 / 3038
页数:12
相关论文
共 28 条
[1]  
BHOGAL N, 1994, J BIOL CHEM, V269, P27269
[2]   Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists [J].
Blaney, FE ;
Raveglia, LF ;
Artico, M ;
Cavagnera, S ;
Dartois, C ;
Farina, C ;
Grugni, M ;
Gagliardi, S ;
Luttmann, MA ;
Martinelli, M ;
Nadler, GMMG ;
Parini, C ;
Petrillo, P ;
Sarau, HM ;
Scheideler, MA ;
Hay, DWP ;
Giardina, GAM .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (11) :1675-1689
[3]   The peptide binding site of the substance P (NK-1) receptor localized by a photoreactive analogue of substance P: Presence of a disulfide bond [J].
Boyd, ND ;
Kage, R ;
Dumas, JJ ;
Krause, JE ;
Leeman, SE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :433-437
[4]   LIGAND-BINDING TO THE BETA-ADRENERGIC-RECEPTOR INVOLVES ITS RHODOPSIN-LIKE CORE [J].
DIXON, RAF ;
SIGAL, IS ;
RANDS, E ;
REGISTER, RB ;
CANDELORE, MR ;
BLAKE, AD ;
STRADER, CD .
NATURE, 1987, 326 (6108) :73-77
[5]   Conserved polar residues in the transmembrane domain of the human tachykinin NK2 receptor:: functional roles and structural implications [J].
Donnelly, D ;
Maudsley, S ;
Gent, JP ;
Moser, RN ;
Hurrell, CR ;
Findlay, JBC .
BIOCHEMICAL JOURNAL, 1999, 339 :55-61
[6]   SR-48968, A NEUROKININ-A (NK2) RECEPTOR ANTAGONIST [J].
EMONDSALT, X ;
ADVENIER, C ;
CROCI, T ;
MANARA, L ;
NELIAT, G ;
PONCELET, M ;
PROIETTO, V ;
SANTUCCI, V ;
SOUBRIE, P ;
VANBROECK, D ;
VILAIN, P ;
LEFUR, G ;
BRELIERE, JC .
REGULATORY PEPTIDES, 1993, 46 (1-2) :31-36
[7]   Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist [J].
EmondsAlt, X ;
Advenier, C ;
Cognon, C ;
Croci, T ;
Daoui, S ;
Ducoux, JP ;
Landi, M ;
Naline, E ;
Neliat, G ;
Poncelet, M ;
Proletto, V ;
VanBroeck, D ;
Vilain, P ;
Soubrie, P ;
LeFur, G ;
Maffrand, JP ;
Breliere, JC .
NEUROPEPTIDES, 1997, 31 (05) :449-458
[8]   CHARACTERIZATION OF THE BINDING-SITES OF [H-3] SR-48968, A POTENT NONPEPTIDE RADIOLIGAND ANTAGONIST OF THE NEUROKININ-2 RECEPTOR [J].
EMONDSALT, X ;
GOLLIOT, F ;
POINTEAU, P ;
LEFUR, G ;
BRELIERE, JC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 191 (03) :1172-1177
[9]  
FONG TM, 1992, BIOCHEMISTRY-US, V31, P11816
[10]  
GETHER U, 1994, MOL PHARMACOL, V45, P500